The TB Alliance and its partners have completed patient enrollment in REMox TB, a global Phase III clinical trial, which may result in the registration of the first new drug approved for the treatment of drug-sensitive TB in nearly 50 years. REMox TB was designed to test whether a moxifloxacin-containing treatment regimen of just four months can cure drug-sensitive TB patients at rates that are non-inferior to those achieved with the standard six-month TB regimen.  In total, more than 1,900 patients were enrolled in REMox TB. To read Prof Stephen Gillespie's Statement from University of St Andrews on Completion of Enrollment in REMox TB click here